INFLAMMATION AND INFLAMMATORY BOWEL DISEASE

Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG

C Prantera, M L Scribano, G Falasco, A Andreoli, C Luzi

Division of Gastroenterology, Azienda Ospedaliera S Camillo-Forlanini, Rome, Italy

Correspondence to:
Correspondence to:
Dr C Prantera, Divisione di Gastroenterologia, Azienda Ospedaliera S Camillo-Forlanini, Via Portuense, 292, 00149 Roma, Italy;
prantera{at}tin.it

Background and aims: Experimental studies have shown that luminal bacteria may be involved in Crohn's disease. Probiotics are a possible alternative to antibiotics. The aim of this randomised placebo controlled study was to determine if Lactobacillus GG, given by mouth for one year, could prevent Crohn's recurrent lesions after surgery or to reduce their severity.

Methods: Patients operated on for Crohn's disease in whom all of the diseased gut had been removed were randomly allocated to receive 12 billion colony forming units of Lactobacillus or identical placebo for one year. Ileocolonoscopy was performed at the end of the trial or at the onset of symptoms. Endoscopic recurrence was defined as grade 2 or higher of Rutgeerts scoring system.

Results: Eight of 45 patients were excluded from the trial (three for non-compliance and five for protocol violations). Clinical recurrence was ascertained in three (16.6%) patients who received Lactobacillus and in two (10.5%) who received placebo. Nine of 15 patients in clinical remission on Lactobacillus (60%) had endoscopic recurrence compared with six of 17 (35.3%) on placebo (p=0.297). There were no significant differences in the severity of the lesions between the two groups.

Conclusions: Lactobacillus GG seems neither to prevent endoscopic recurrence at one year nor reduce the severity of recurrent lesions.

Keywords: Crohn's disease; probiotics; lactobacillus GG; gut bacteria; endoscopic recurrence

Abbreviations: CDAI, Crohn's disease activity index; LGG, Lactobacillus GG; cfu, colony forming units

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Digest

Ian Forgacs
Gut 2002 51: 301. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Barbas, A. S., Lesher, A. P., Thomas, A. D., Wyse, A., Devalapalli, A. P., Lee, Y.-H., Tan, H.-E., Orndorff, P. E., Bollinger, R. R., Parker, W. (2009). Altering and Assessing Persistence of Genetically Modified E. coli MG1655 in the Large Bowel. Exp. Biol. Med. 234: 1174-1185 [Abstract] [Full Text]  
• Carvalho, F. A., Barnich, N., Sivignon, A., Darcha, C., Chan, C. H.F., Stanners, C. P., Darfeuille-Michaud, A. (2009). Crohn's disease adherent-invasive Escherichia coli colonize and induce strong gut inflammation in transgenic mice expressing human CEACAM. JEM 206: 2179-2189 [Abstract] [Full Text]  
• Rigby, R J, Hunt, M R, Scull, B P, Simmons, J G, Speck, K E, Helmrath, M A, K Lund, P (2009). A new animal model of postsurgical bowel inflammation and fibrosis: the effect of commensal microflora. Gut 58: 1104-1112 [Abstract] [Full Text]  
• Lebeer, S., Vanderleyden, J., De Keersmaecker, S. C. J. (2008). Genes and Molecules of Lactobacilli Supporting Probiotic Action. Microbiol. Mol. Biol. Rev. 72: 728-764 [Abstract] [Full Text]  
• Guzy, C., Paclik, D., Schirbel, A., Sonnenborn, U., Wiedenmann, B., Sturm, A. (2008). The probiotic Escherichia coli strain Nissle 1917 induces {gamma}{delta} T cell apoptosis via caspase- and FasL-dependent pathways. Int Immunol 20: 829-840 [Abstract] [Full Text]  
• Corthesy, B., Gaskins, H. R., Mercenier, A. (2007). Cross-Talk between Probiotic Bacteria and the Host Immune System. J. Nutr. 137: 781S-790S [Abstract] [Full Text]  
• de Vrese, M., Marteau, P. R. (2007). Probiotics and Prebiotics: Effects on Diarrhea. J. Nutr. 137: 803S-811S [Abstract] [Full Text]  
• Prantera, C (2006). Probiotics for Crohn's disease: what have we learned?. Gut 55: 757-759 [Full Text]  
• Marteau, P, Lemann, M, Seksik, P, Laharie, D, Colombel, J F, Bouhnik, Y, Cadiot, G, Soule, J C, Bourreille, A, Metman, E, Lerebours, E, Carbonnel, F, Dupas, J L, Veyrac, M, Coffin, B, Moreau, J, Abitbol, V, Blum-Sperisen, S, Mary, J Y (2006). Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut 55: 842-847 [Abstract] [Full Text]  
• Caprilli, R, Gassull, M A, Escher, J C, Moser, G, Munkholm, P, Forbes, A, Hommes, D W, Lochs, H, Angelucci, E, Cocco, A, Vucelic, B, Hildebrand, H, Kolacek, S, Riis, L, Lukas, M, de Franchis, R, Hamilton, M, Jantschek, G, Michetti, P, O'Morain, C, Anwar, M M, Freitas, J L, Mouzas, I A, Baert, F, Mitchell, R, Hawkey, C J, for the European Crohn's and Colitis Organisation, (2006). European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 55: i36-i58 [Abstract] [Full Text]  
• Menard, S., Laharie, D., Asensio, C., Vidal-Martinez, T., Candalh, C., Rullier, A., Zerbib, F., Megraud, F., Matysiak-Budnik, T., Heyman, M. (2005). Bifidobacterium breve and Streptococcus thermophilus Secretion Products Enhance T Helper 1 Immune Response and Intestinal Barrier in Mice. Exp. Biol. Med. 230: 749-756 [Abstract] [Full Text]  
• Dray, X., Marteau, P. (2005). The Use of Enteral Nutrition in the Management of Crohn's Disease in Adults. JPEN J Parenter Enteral Nutr 29: S166-S172 [Abstract] [Full Text]  
• Jenkins, B., Holsten, S., Bengmark, S., Martindale, R. (2005). Probiotics: A Practical Review of Their Role in Specific Clinical Scenarios. Nutr Clin Pract 20: 262-270 [Abstract] [Full Text]  
• Di Giacinto, C., Marinaro, M., Sanchez, M., Strober, W., Boirivant, M. (2005). Probiotics Ameliorate Recurrent Th1-Mediated Murine Colitis by Inducing IL-10 and IL-10-Dependent TGF-{beta}-Bearing Regulatory Cells. J. Immunol. 174: 3237-3246 [Abstract] [Full Text]  
• Furrie, E, Macfarlane, S, Kennedy, A, Cummings, J H, Walsh, S V, O'Neil, D A, Macfarlane, G T (2005). Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 54: 242-249 [Abstract] [Full Text]  
• Kruis, W, Fric, P, Pokrotnieks, J, Lukas, M, Fixa, B, Kascak, M, Kamm, M A, Weismueller, J, Beglinger, C, Stolte, M, Wolff, C, Schulze, J (2004). Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53: 1617-1623 [Abstract] [Full Text]  
• Gill, H S, Guarner, F (2004). Probiotics and human health: a clinical perspective. Postgrad. Med. J. 80: 516-526 [Abstract] [Full Text]  
• Menard, S, Candalh, C, Bambou, J C, Terpend, K, Cerf-Bensussan, N, Heyman, M (2004). Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport. Gut 53: 821-828 [Abstract] [Full Text]  
• Ghosh, S, van Heel, D, Playford, R J (2004). Probiotics in inflammatory bowel disease: is it all gut flora modulation?. Gut 53: 620-622 [Full Text]  
• Reid, G., Jass, J., Sebulsky, M. T., McCormick, J. K. (2003). Potential Uses of Probiotics in Clinical Practice. Clin. Microbiol. Rev. 16: 658-672 [Abstract] [Full Text]  
• Jonkers, D., Stockbrugger, R. (2003). Probiotics and inflammatory bowel disease. JRSM 96: 167-171 [Full Text]  
• Garcia de Tena, J., Espinosa, L. M., Alvarez-Mon, M., Famularo, G., Trinchieri, V., De Simone, C., Marchetti, F., Martelossi, S., Ventura, A., Mohammed, F., Podolsky, D. K. (2002). Inflammatory Bowel Disease. NEJM 347: 1982-1984 [Full Text]  

eLetters:

Read all eLetters

Repeating the same mistakes as other studies

Andy R Weale, et al.

Gut Online, 7 Nov 2002 [Full text]

Response to Dr A R Weale et al

Cosimo Prantera

Gut Online, 28 Nov 2002 [Full text]